Amplify Weight Loss Drug & Treatment ETF
THNR
2 hedge funds and large institutions have $187K invested in Amplify Weight Loss Drug & Treatment ETF in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
29.52% less ownership
Funds ownership: 35.86% → 6.34% (-30%)
50% less funds holding
Funds holding: 4 → 2 (-2)
87% less capital invested
Capital invested by funds: $1.39M → $187K (-$1.2M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$42.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
-$719K |
| 2 |
Jane Street
New York
|
-$536K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
1
Harbour Investments
Madison,
Wisconsin
| $129K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $58K | +$42.4K | +1,955 | +327% |
|
|
GS
3
GTS Securities
New York
| – | -$719K | -33,373 | Closed |
|
|
4
Jane Street
New York
| – | -$536K | -24,891 | Closed |
|
THNR Hedge Fund Activity: Q2 2025 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q2 2025, worth a combined $187K — down 87% from $1.39M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of THNR and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $42.4K. The largest seller was GTS Securities, exiting entirely with an estimated $719K sold.
- 2 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q2 2025, down from 4 in Q1 2025.
- Funds reported $187K of Amplify Weight Loss Drug & Treatment ETF stock for Q2 2025, down 87% quarter-over-quarter.
- 0 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q2 2025 and 2 closed out, a net change of -2 holders.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q2 2025 was UBS Group, an estimated $42.4K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q2 2025 was GTS Securities, an estimated $719K sold.
Based on aggregated 13F filings for Q2 2025.